Treatment patterns, healthcare resource utilization and costs of HER2-negative gastric/gastroesophageal junction cancer Suppl materials

This study was funded by Astellas Pharma, Inc. R Fuldeore, LP Chaves, Q Feng, N Rozario, D Nimke and S Braun are employees of Astellas Pharma, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing and editorial support were provided by K Mickle, B Lesher and C Mirvis from OPEN Health, Bethesda, MD, and by C Cadmus from Peloton Advantage, an OPEN Health company, Parsippany, NJ, and were funded by Astellas Pharma, Inc.